Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-27

Clinical Trial Update: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma [Phase 2]

View source ↗

Summary

Phase II trial update reporting results for Cediranib (AZD2171) in alveolar soft part sarcoma; study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cediranib (AZD2171) (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Alveolar Soft Part | Phase 2 | Status: COMPLETED | Results posted: 2021-04-27